Results 91 to 100 of about 56,993 (185)

High prominence:Low prominence ratios over time.

, 2015
(A) capecitabine, (B) eldecalcitol, (C) epoetin beta pegol, (D) peginterferon alfa-2a, and (E) sevelamer hydrochloride.
Seigo Okugawa (733308), Kotonari Aoki (733302), Terumi Nakayama (733307), Takumi Kobayashi (733305), Takuya Kawamata (733303), Minami Tomita (733310), Yoshihiko Sugimura (733309), Yoichiro Takahashi (733311), Hiroshi Kuriki (733306), Shinichi Matsuda (733301), Tetsuji Kimotsuki (733304)   +10 more
core   +1 more source

Comparative in vitro cytogenetic analysis of calcium carbonate and sevelamer hydrochloride agents used by patients with hyperphosphatemia.

, 2019
TEZ12037Tez (Yüksek Lisans) -- Çukurova Üniversitesi, Adana, 2019.Kaynakça (s. 85-100) var.XVII, 101 s. :_res. (bzs. rnk), tablo ;_29 cm.Bu çalışma, hiperfosfatemili hastaların tedavisinde sıklıkla reçete edilen ve fosfat bağlayıcı grubunda yer alan ...
Ulaya, Goulzar
core   +1 more source

Sevelamer hydrochloride attenuates kidney and cardiovascular calcifications in long-term experimental uremia

, 2003
Sevelamer hydrochloride attenuates kidney and cardiovascular calcifications in long-term experimental uremia.BackgroundIn chronic renal failure (CRF), hyperphosphatemia and an elevated calcium-phosphate product are associated with vascular calcification ...
E. Slatopolsky, J. Finch, A. S. Dusso, S. K. Burke, M. E. Staniforth, H. Liapis, M. Cozzolino   +6 more
core   +1 more source

Efficacy and tolerability of sevelamer carbonate in hyperphosphatemic patients who have chronic kidney disease and are not on dialysis

, 2008
BACKGROUND AND OBJECTIVES: Sevelamer carbonate is an improved, buffered form of sevelamer hydrochloride developed for the treatment of hyperphosphatemia in patients with chronic kidney disease.
Kalra, P.A., Ketteler, M., Chasan-Taber, S., Pritchard, N., Rix, M., Oestergaard, O., Duggal, A., Fan, S., Heaton, J.   +8 more
core   +2 more sources

Sevelamer carbonate increases serum bicarbonate in pediatric dialysis patients.

, 2010
Sevelamer hydrochloride (HCl), a calcium-free phosphate binder, is increasingly used due to concerns related to calcium exposure and the development of vascular calcifications.
Amin, Nimisha, Gonzalez, Elsa, Zaritsky, Joshua, Schomberg, John, Salusky, Isidro B   +4 more
core   +1 more source

The proportion of adverse drug reactions reported to the manufacturer within 2 weeks of onset.

, 2015
(A) capecitabine, (B) eldecalcitol, (C) epoetin beta pegol, (D) peginterferon alfa-2a, and (E) sevelamer hydrochloride. Error bars represent the 95% confidence intervals.
Seigo Okugawa (733308), Kotonari Aoki (733302), Terumi Nakayama (733307), Takumi Kobayashi (733305), Takuya Kawamata (733303), Minami Tomita (733310), Yoshihiko Sugimura (733309), Yoichiro Takahashi (733311), Hiroshi Kuriki (733306), Shinichi Matsuda (733301), Tetsuji Kimotsuki (733304)   +10 more
core   +1 more source

Practical use of sevelamer in chronic kidney disease patients on dialysis in People’s Republic of China [PDF]

, 2015
Lin Meng,1,2 Bin Fu1 1Department of Nephrology, Second Affiliated Hospital to Tianjin University of Traditional Chinese Medicine, Tianjin, People’s Republic of China; 2Tianjin University of Traditional Chinese Medicine, Tianjin, People’s ...
Fu B, Meng L
core  

Adverse drug reaction reporting trend for 5 drugs.

, 2015
Total number of individual case safety reports for (A) capecitabine, (B) eldecalcitol, (C) epoetin beta pegol, (D) peginterferon alfa-2a, and (E) sevelamer hydrochloride.
Seigo Okugawa (733308), Kotonari Aoki (733302), Terumi Nakayama (733307), Takumi Kobayashi (733305), Takuya Kawamata (733303), Minami Tomita (733310), Yoshihiko Sugimura (733309), Yoichiro Takahashi (733311), Hiroshi Kuriki (733306), Shinichi Matsuda (733301), Tetsuji Kimotsuki (733304)   +10 more
core   +1 more source

Effect of switching from sevelamer hydrochloride to lanthanum carbonate on metabolic acidosis in dialysis patients

Treatments for hyperphosphatemia in dialysis patients include dietary therapy and oral administration of phosphate binders; however, it has recently been suggested that oral administration of sevelamer hydrochloride, a phosphate binder, may cause ...
Uramatsu, Tadashi, Nishino, Tomoya, Hirose, Misaki, Funakoshi, Satoshi, Kohno, Shigeru, Harada, Takashi, Minami, Kana, Arai, Hideyuki, Obata, Yoko, Yamashita, Hiroshi   +9 more
core  

Biomechanical Properties of Bones from Rats Treated with Sevelamer [PDF]

, 2011
Sevelamer hydrochloride is used for ten years in patients on dialysis as a phosphate binder.We have previously shown that oral application of sevelamer prevents the bone loss and increases the bone volume in ovariectomized rats1.
Tikvica, Ana, Drača, Natasa, Brnčić, Mladen, Vukičević, Slobodan, Eljuga, Domagoj, Semenski, Damir   +5 more
core